Should You Buy Sage Therapeutics (SAGE) Ahead of Earnings?
Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Investors are always looking for stocks that are poised to beat at earnings season and Sage Therapeutics SAGE may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Sage Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for SAGE in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.67 per share for SAGE, compared to a broader Zacks Consensus Estimate of a loss of $1.84 per share. This suggests that analysts have very recently bumped up their estimates for SAGE, giving the stock a Zacks Earnings ESP of +9.35% heading into earnings season.
Sage Therapeutics, Inc. Price and EPS Surprise
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that SAGE has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Bbuy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Sage Therapeutics, and that a beat might be in the cards for the upcoming report.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sage Therapeutics, Inc. (SAGE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research